Compare NBIX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | EXEL |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.4B |
| IPO Year | 1996 | 2000 |
| Metric | NBIX | EXEL |
|---|---|---|
| Price | $156.33 | $52.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 21 |
| Target Price | ★ $180.91 | $46.50 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.95 | ★ 57.95 |
| EPS | ★ 1.91 | 0.79 |
| Revenue | $161,626,000.00 | ★ $452,477,000.00 |
| Revenue This Year | $24.73 | $13.61 |
| Revenue Next Year | $13.14 | $13.13 |
| P/E Ratio | $83.51 | ★ $67.09 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $33.76 |
| 52 Week High | $169.57 | $53.93 |
| Indicator | NBIX | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 57.89 |
| Support Level | $153.30 | $40.17 |
| Resistance Level | $160.08 | N/A |
| Average True Range (ATR) | 5.25 | 1.56 |
| MACD | -1.33 | -0.04 |
| Stochastic Oscillator | 14.33 | 73.05 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.